Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J.
Gu R, et al. Among authors: wang h, wang j, wang y, wang m.
J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.
J Hematol Oncol. 2020.
PMID: 32894185
Free PMC article.
Clinical Trial.